Showing 2101-2110 of 2319 results for "".
- Psoria-Shield, Inc. Names Dr. Steven Feldman as Scientific Advisorhttps://practicaldermatology.com/news/psoria-shield-inc-names-dr-steven-feldman-as-scientific-advisor/2458754/Psoria-Shield, Inc. Names Dr. Steven Feldman as Scientific Advisor Wellness Center USA, Inc.’s wholly owned subsidiary, Psoria-Shield, Inc. (PSI) named Steven Feldman, MD, PhD as Scientific Advisor. Dr. Feldman is a Professor of Dermatology, Professor of Pathology, and Professor of
- FDA Approves Expanded Indication for Merck's Keytruda for Treatment of Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-expanded-indication-for-mercks-keytruda-for-treatment-of-advanced-melanoma/2458773/The FDA has approved an expanded indication for Merck’s Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indicat
- New Rosacea Research Findings Presented During SID Annual Meetinghttps://practicaldermatology.com/news/new-rosacea-research-findings-presented-during-sid-annual-meeting/2458777/Medical scientists reviewed research on the microbiome, genetics and pathophysiology of rosacea and presented results of new studies funded by the National Rosacea Society (NRS) during its research workshop at the Society for Investigative Dermatology annual meeting. “Research suppo
- AADA Supports New Bill to Protect Senior Access to Dermatologic Carehttps://practicaldermatology.com/news/aada-supports-new-bill-to-protect-senior-access-to-dermatologic-care/2458781/The American Academy of Dermatology Association (AADA) supports the Medicare Advantage Bill of Rights Act, introduced by Sen. Sherrod Brown (D-Oh.) and Rep. Rosa DeLauro (D-Conn.). If passed, the legislation would ensure that patients will have adequate physician networks in their Medicare Advant
- ASDS Awards Inagural Research Grant Recipient of Fredric S. Brandt, MD, Innovations in Aesthetics Fellowshiphttps://practicaldermatology.com/news/asds-awards-inagural-research-grant-recipient-of-fredric-s-brandt-md-innovations-in-aesthetics-fellowship/2458790/Abigail Waldman, MD, of Chicago, has been chosen as the inaugural research grant recipient of the Fredric S. Brandt, MD, Innovations in Aesthetics Fellowship Fund. Dr. Waldman was awarded $41,500 for her research project entitled “Patient Motivations and Preferences Regarding the De
- Review Does Not Support Monthly Lab Testing for Oral Isotretinoin Use for Acnehttps://practicaldermatology.com/news/review-does-not-support-monthly-lab-testing-for-oral-isotretinoin-use-for-acne/2458793/A review of medical literature does not support monthly laboratory testing for all patients who are using standard doses of the acne medication isotretinoin, according to an article published online by JAMA Dermatology</
- Novartis receives FDA regular approval for Tafinlar + Mekinist for Melanomahttps://practicaldermatology.com/news/novartis-receives-fda-regular-approval-for-tafinlar-mekinist-for-melanoma/2458804/The FDA granted regular approval for the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) from Novartis for the treatment of patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma as detected by an FDA-approved test. This is th
- Cosmetic Bootcamp University Exceeds Goalshttps://practicaldermatology.com/news/cosmetic-bootcamp-university-a-success/2458815/Now completing its session in Philadelphia, the Cosmetic Bootcamp University session has exceeded goals, organizers report. Cosmetic Bootcamp seeks to improve patient outcomes in a manner not possible at other meetings by focusing on core specialists in dermatology, plastic surgery, op
- Diplomat Pharmacy to Dispense Cotellic®https://practicaldermatology.com/news/diplomat-pharmacy-to-dispense-cotellic/2458816/Diplomat Pharmacy, Inc. will dispense Cotellic® (cobimetinib) in combination with the BRAF inhibitor Zelboraf® (vemurafenib) to treat patients with advanced melanoma that is unrespectable or metastatic. The com
- Syneron Candela Announces New FDA Clearance for the CO2RE Systemhttps://practicaldermatology.com/news/syneron-candela-announces-new-fda-clearance-for-the-co2re-system/2458825/The FDA has granted numerous additional indications for use of Syneron Medical Ltd.’s CO2RE CO2 device. This clearance, including more than 90 specific indications in total, significantly expands the business opportunity for CO2RE users for high patient dema